

Dkt. 57746-A-PCT-US/JET/ADM/PL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mohammad R. Marzabadi, et al
U.S. Serial No. : 10/019,881
Filed : December 27, 2001
For : Selective NPY (Y5) Antagonists

1185 Avenue of the Americas
New York, New York 10036
August 16, 2002

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Supplemental Information Disclosure Statement
Pursuant To 37 C.F.R. §1.97(b)(3)

This Supplemental Information Disclosure Statement is submitted to supplement the Information Disclosure Statement filed on December 27, 2001 in connection with the subject application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit A**) and attached hereto as **Exhibits B-Q**:

1. Wettstein, et al., "Central Nervous System Pharmacology of Neuropeptide Y, (1995) *Pharmac Ther.* 65:397-414 (**Exhibit B**);
2. U.S. Patent No. 6,340,683, issued January 22, 2002, Marzabadi, et al. (**Exhibit C**);
3. U.S. Patent No. 6,225,330, issued May 1, 2001, Marzabadi, et al. (**Exhibit D**);
4. U.S. Patent No. 6,222,040, issued April 24, 2001,

GP 16 26
RECEIVED
AUG 21 2002
TECH CENTER 1600/2900

Applicants: Mohammad R. Marzabadi et al.
U.S. Serial No.: 10/019,881
Filed: December 27, 2001
Page 2

Marzabadi, et al. (**Exhibit E**);

5. U.S. Patent No. 6,218,408 B1, issued April 17, 2001, Marzabadi, et al. (**Exhibit F**);
6. U.S. Patent No. 6,214,853 B1, issued April 10, 2001, Marzabadi, et al. (**Exhibit G**);
7. U.S. Patent No. 6,124,331, issued September 26, 2000, Marzabadi, et al. (**Exhibit H**);
8. U.S. Patent No. 3,128,272, issued April 7, 1964, Wear, et al. (**Exhibit I**);
9. PCT International Publication No. WO 01/23389, Horvath, R, et al., published April 5, 2001 (**Exhibit J**);
10. Mohammad R. Marzabadi et al., Selective NPY (Y5) Antagonists (Triazines), U.S. Serial No. 10/037,859, filed January 3, 2002 (**Exhibit K**);
11. Mohammad R. Marzabadi et al., Selective NPY (Y5) Antagonists, U.S. Serial No. 10/009,849, filed October 22, 2001 (**Exhibit L**);
12. PCT International Publication No. WO 01/44201, published June 21, 2001 (**Exhibit M**);
13. PCT International Publication No. WO 01/64675, published September 7, 2001 (**Exhibit N**);
14. PCT International Publication No. WO 00/64880, published

Applicants: Mohammad R. Marzabadi et al.
U.S. Serial No.: 10/019,881
Filed: December 27, 2001
Page 3

November 2, 2000 (**Exhibit O**);

15. PCT International Publication No. WO 99/01128, published January 14, 1999 (**Exhibit P**); and
16. McNally JJ et al., N-(Sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor. Bioorganic & Medicinal Chemistry Letters 10: 212-216 (2000) (**Exhibit Q**).

The references listed above as **Exhibit I-J** were cited in a Supplementary Partial European Search Report issued May 31, 2002 in connection with European Patent Application No. 00923566.4; a copy of the Search Report is attached hereto as **Exhibit R**.


The references listed above as **Exhibit M-Q** were cited in a Supplementary Partial European Search Report issued July 31, 2002 in connection with European Patent Application 00923603.5; a copy of the Search Report is attached hereto as **Exhibit S**.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invite the Examiner to telephone the number provided below.

Applicants: Mohammad R. Marzabadi et al.
U.S. Serial No.: 10/019,881
Filed: December 27, 2001
page 4


Applicants are filing this Information Disclosure Statement under 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan D. Miller
Registration No. 42,889
Attorneys for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.


Alan D. Miller Date
Reg. No. 42,889

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant
Mohammad R. Marzabadi, et alFiling Date
12/27/01

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	6 3 4 0 6 8 3	1/22/02	Marzabadi, et al (Exhibit C)			
	6 2 2 5 3 3 0	5/01/01	Marzabadi, et al (Exhibit D)			
	6 2 2 2 0 4 0	4/24/01	Marzabadi, et al (Exhibit E)			
	6 2 1 8 4 0 8	4/17/01	Marzabadi, et al (Exhibit F)			
	6 2 1 4 8 5 3	4/10/01	Marzabadi, et al (Exhibit G)			
	6 1 2 4 3 3 1	9/26/00	Marzabadi, et al (Exhibit H)			
	3 1 2 8 2 7 2	4/7/64	Wear, et al (Exhibit I)			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	0 1 2 3 3 8 9	4/5/01	PCT (Exhibit J)				
	0 1 4 4 2 0 1	6/21/01	PCT (Exhibit M)				
	0 1 6 4 6 7 5	9/7/01	PCT (Exhibit N)				
	0 0 6 4 8 8 0	11/2/00	PCT (Exhibit O)				
	9 9 0 1 1 2 8	1/14/99	PCT (Exhibit P)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Wettstein, et al., "Central Nervous System Pharmacology of Neuropeptide Y, (1995) <i>Pharmac Ther.</i> 65:397-414 (Exhibit B).
	Mohammad R. Marzabadi et al., Selective NPY (Y5) Antagonists (Triazines), U.S. Serial No. 10/037,859, filed January 3, 2002 (Exhibit K)
	Mohammad R. Marzabadi et al., Selective NPY (Y5) Antagonists, U.S. Serial No. 10/009,849, filed October 22, 2001 (Exhibit L)
	McNally JJ et al., <i>N</i> -(Sulfonamido)alkyl[tetrahydro-1 <i>H</i> -benzo[<i>e</i>]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor. <i>Bioorganic & Medicinal Chemistry Letters</i> 10: 212-216 (2000) (Exhibit Q)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Mohammad R. Marzabadi, et al.
U.S. Serial No.: 10/019,881
Filed: December 27, 2001
Exhibit A